Loading...
01/11 03:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session reveal strong financial health, optimistic guidance, and significant progress in clinical trials. Enrollment is ahead of projections, and the company is on track with its BLA filing timeline. The positive market reaction is bolstered by the announcement of new drugs entering the market and strong patient and physician interest. Despite some management responses being unclear, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
Cash, cash equivalents, and marketable securities $630.5 million as of June 30, 2025, compared to $861.7 million as of December 31, 2024. The decrease reflects the company's ongoing investments in its clinical pipeline and operational infrastructure.
Collaboration revenue $14.2 million during Q2 2025, compared to $6.9 million during the prior year quarter. This $7.3 million increase was mainly driven by cost reimbursements related to the collaboration with Regeneron Pharmaceuticals.
R&D expenses $97 million during Q2 2025, compared to $114.2 million during the prior year quarter. This $17.2 million decrease was primarily driven by reductions in employee-related expenses, stock-based compensation, research materials, and contracted services, offset by increased expenses for advancing lead programs.
Stock-based compensation in R&D expenses $14.1 million for Q2 2025.
G&A expenses $27.2 million during Q2 2025, compared to $31.8 million during the prior year quarter. This $4.6 million decrease was primarily related to lower stock-based compensation, offset in part by increased expenses for the ongoing build-out of commercial infrastructure.
Stock-based compensation in G&A expenses $8 million for Q2 2025.
Lonvo-z for HAE: Expected to launch in the first half of 2027. Phase III studies are enrolling faster than expected, with recruitment completed and randomization expected in Q3 2025. Lonvo-z is positioned as a one-time therapy with a unique profile, offering freedom from attacks and chronic treatment.
Nex-z for ATTR Amyloidosis: Phase III studies are progressing well, with enrollment targets increased to 1,200 patients for cardiomyopathy trials. Nex-z shows potential as a differentiated competitor in the market, with strong clinical data supporting its efficacy in reducing TTR levels and improving patient outcomes.
ATTR Amyloidosis Market: Nex-z is positioned to be a formidable competitor in this large and growing market, with strong demand from patients and physicians.
HAE Market: Lonvo-z addresses a high unmet need, with significant interest from patients and physicians, indicating strong market potential.
Operational Efficiency: Phase III studies for Lonvo-z and Nex-z are enrolling faster than expected, reflecting operational excellence. The company has also built out its commercial and medical affairs leadership teams to support future product launches.
Financial Restructuring: Restructuring efforts have delivered expected benefits, supporting a financial runway into the first half of 2027.
Strategic Expansion: Enrollment targets for Nex-z cardiomyopathy trials increased to 1,200 patients to enhance data robustness and market competitiveness.
Leadership Transition: Chief Medical Officer David Lebwohl announced his retirement effective August 2026, with a successor search underway to ensure a seamless transition.
Regulatory Hurdles: The expansion of the Phase III study for nex-z in ATTR cardiomyopathy to 1,200 patients is subject to health authority review, which could delay timelines or require additional resources.
Financial Risks: The company’s cash balance of $630.5 million is projected to fund operations only until the first half of 2027, which may necessitate additional funding or partnerships to sustain operations.
Operational Challenges: The rapid enrollment in multiple Phase III studies, while a positive indicator of demand, could strain operational resources and require careful management to maintain quality and timelines.
Market Competition: The TTR treatment landscape is evolving with new agents becoming available, which could impact the competitive positioning of nex-z.
Strategic Execution Risks: The company is undergoing a significant build-out of its commercial and medical teams, which introduces risks related to integration, execution, and alignment with strategic goals.
Clinical Trial Risks: The reliance on strong patient and physician interest for enrollment in trials could be impacted by unforeseen factors, potentially delaying study completion or affecting data quality.
Launch of Lonvo-z for HAE: The company expects to launch Lonvo-z for HAE in the first half of 2027.
Enrollment in Phase III studies: Enrollment for all three Phase III studies (Lonvo-z and Nex-z) is progressing faster than expected. The company anticipates completing enrollment earlier for HAE and ATTR polyneuropathy programs and enrolling more patients in the cardiomyopathy program than initially planned.
Expansion of Nex-z Phase III study: The company plans to increase enrollment in the Nex-z Phase III study for ATTR cardiomyopathy to approximately 1,200 patients, subject to health authority review, to provide a more robust data set.
Completion of Magnitude enrollment: The company aims to complete Magnitude enrollment by early 2027.
Completion of HAELO study recruitment: Recruitment for the HAELO study of Lonvo-z has ended, and randomization is expected to be completed during the third quarter of 2025.
Completion of Magnitude 2 enrollment: Enrollment for the Magnitude 2 study for hereditary ATTR polyneuropathy is expected to be completed in the first half of 2026.
Regulatory milestones: The company plans to achieve several clinical and regulatory milestones before the end of 2026.
Financial guidance: The company expects a year-over-year decline in GAAP operating expenses by approximately 10% in 2025 and has sufficient cash to fund operations into the first half of 2027.
The selected topic was not discussed during the call.
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
The earnings call summary and Q&A session reveal strong financial health, optimistic guidance, and significant progress in clinical trials. Enrollment is ahead of projections, and the company is on track with its BLA filing timeline. The positive market reaction is bolstered by the announcement of new drugs entering the market and strong patient and physician interest. Despite some management responses being unclear, the overall sentiment is positive, suggesting a stock price increase of 2% to 8% over the next two weeks.
The earnings call summary presents a mixed outlook: while there are cost reductions and strategic pipeline prioritizations, there are also declines in collaboration revenue and workforce reductions that could impact operations. The Q&A section reveals some management avoidance on specifics, potentially raising concerns. Despite this, the company's financial health appears stable with a substantial cash reserve, and there is optimism about future product launches. Given the market cap, the stock price reaction is likely to remain within a neutral range, reflecting both positive and negative factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
